Patient-centred outcomes in primary care management of COPD - What do recent clinical trial data tell us?

Primary Care Respiratory Journal

Volumn 13, Issue 4, 2004, Pages 185-197

  Haughney, John ^a   Gruffydd Jones, Kevin ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Wiltshire UK ^*  (United Kingdom)

Author keywords

Budesonide; COPD; Exacerbations; Fluticasone; Formoterol; Health related quality of life; Inhaled corticosteroid; Long acting 2 agonist; Salmeterol; Symptoms; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM; UNCLASSIFIED DRUG;

ACCURACY; ADRENAL CORTEX DISEASE; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HEMATOMA; HUMAN; LUNG FUNCTION; MORTALITY; OSTEOLYSIS; PATIENT; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIMARY MEDICAL CARE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SAFETY; SIDE EFFECT; SYMPTOM; THRUSH; TREATMENT OUTCOME; WELLBEING; XEROSTOMIA;

EID: 8844248694     PISSN: 14714418     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcrj.2004.06.006     Document Type: Review

References (88)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Institutes of Health (NIH publication No. 2701); 2003.
2. British Thoracic Society BTS guidelines for the management of chronic obstructive pulmonary disease Thorax. 52 Suppl 5 1997 S1 S28
3. C.J. Murray, and A.D. Lopez Alternative projections of mortality and disability by cause. 1990-2020: Global Burden of Disease Study Lancet. 349 1997 1498 1504
4. A. Crockett Screening older patients for obstructive airways disease Thorax. 54 1999 472 473
5. R. Casaburi, D.D. Briggs Jr., J.F. Donohue, C.W. Serby, S.S. Menjoge, and TJ. Witek Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group Chest. 118 2000 1294 1302
6. R. Casaburi, D.A. Mahler, and P.W. Jones A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224
7. J.F. Donohue, J.A. van Noord, and E.D. Bateman A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest. 122 2002 47 55
8. W. Vincken, J.A. van Noord, and A.P. Greefhorst Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Eur Respir J 19 2002 209 216
9. D.A. Mahler, P. Wire, and D. Horstman Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med. 166 2002 1084 1091
10. P. Calverley, R. Pauwels, and J. Vestbo Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet. 361 2003 449 456
11. P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919
12. N.A. Hanania, P. Darken, and D. Horstman The efficacy and safety of fluticasone proprionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD Chest. 124 2003 834 843
13. W. Szafranski, A. Cukier, and A. Ramirez Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
14. van Schayck OCP, K.F. Rabe, and M. Rudolf COPD: the role of primary care in effective diagnosis, treatment and management Prim Care Respir J 12 2003 16 20
15. D. Price, and M. Duerden Chronic obstructive pulmonary disease BMJ 326 2003 1046 1047
16. E.R. Sutherland, H. Allmers, N.T. Ayas, A.J. Venn, and R.J. Martin Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis Thorax. 58 2003 937 941
17. K. Foglio, M. Carone, M. Pagani, L. Bianchi, P.W. Jones, and N. Ambrosino Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction Respir Med. 94 2000 256 263
18. P.W. Jones, and T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med. 155 1997 1283 1289
19. P.W. Jones Interpreting thresholds for a clinically significant change in health status in asthma and COPD Eur Respir J 19 2002 398 404
20. A.J. McSweeny, I. Grant, R.K. Heaton, K.M. Adams, and R.M. Timms Life quality of patients with chronic obstructive pulmonary disease Arch Intern Med. 142 1982 473 478
21. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire Am Rev Respir Dis. 145 1992 1321 1327
22. C.A. Ketelaars, M.A. Schlosser, R. Mostert, H. Huyer Abu-Saad, R.J. Halfens, and E.F. Wouters Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease Thorax 51 1996 39 43
23. T. Hajiro, K. Nishimura, M. Tsukino, A. Ikeda, H. Koyama, and T. Izumi Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med. 157 1998 785 790
24. V. Bellia, F. Catalano, and N. Scichilone Sleep disorders in the elderly with and without chronic airflow obstruction: the SARA study Sleep. 26 2003 318 323
25. E. Breslin, C. van der Schans, and S. Breukink Perception of fatigue and quality of life in patients with COPD Chest. 114 1998 958 964
26. A.M. Schols, and E.F. Wouters Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease Clin Chest Med. 21 2000 753 762
27. Wouters EFM, E.C. Creutzberg, and AM.W. Schols Systemic effects in COPD Chest. 121 2002 127S 130S
28. D.A. Mahler, K. Faryniarz, and D. Tomlinson Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease Chest. 102 1992 395 401
29. M.T. Elias Hernandez, F. Ortega Ruiz, H. Sanchez Riera, R. Otero Candelera, R. Sanchez Gill, and T. Montemayor Rubio Role of dyspnea in quality of life of the patient with chronic obstructive pulmonary disease Arch Bronconeumol. 35 1999 261 266
30. I. Murdoch, E. Sthl, L. Ahlström, and C-G. Löfdahl Understanding patients' needs: the impact of COPD Eur Respir J 22 Suppl 45 2003 69S
31. D.A. Mahler, D.H. Weinberg, C.K. Wells, and A.R. Feinstein The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes Chest. 85 1984 751 758
32. D.A. Mahler, and C.K. Wells Evaluation of clinical methods for rating dyspnea Chest. 93 1988 580 586
33. R. Carter, D.B. Holiday, C. Nwasuruba, J. Stocks, C. Grothues, and B. Tiep 6-minute walk work for assessment of functional capacity in patients with COPD Chest. 123 2003 1408 1415
34. S.J. Singh, D.L. Smith, M.E. Hyland, and M.D. Morgan A short outpatient pulmonary rehabilitation programme: immediate and longer-term effects on exercise performance and quality of life Respir Med. 92 1998 1146 1154
35. Burki NK Dyspnea Lung 165 1987 269 277
36. A. Noseda, J.P. Carpiaux, J. Schmerber, and J.C. Yernault Dyspnoea assessed by visual analogue scale in patients with chronic obstructive lung disease during progressive and high intensity exercise Thorax. 47 1992 363 368
37. D.L. Cullen, and B. Rodak Clinical utility of measures of breathlessness Respir Care. 47 2002 986 993
38. T. Oga, K. Nishimura, M. Tsukino, T. Hajiro, A. Ikeda, and M. Mishima Relationship between different indices of exercise capacity and clinical measures in patients with chronic obstructive pulmonary disease Heart Lung. 31 2002 374 381
39. M.J. Berry, W.J. Rejeski, N.E. Adair, and D. Zaccaro Exercise rehabilitation and chronic obstructive pulmonary disease stage Am J Respir Crit Care Med. 160 1999 1248 1253
40. K. Stavem, J. Boe, and J. Erikssen Health status, dyspnea, lung function and exercise capacity in patients with chronic obstructive pulmonary disease Int J Tuberc Lung Dis. 3 1999 920 926
41. T. Hajiro, K. Nishimura, M. Tsukino, A. Ikeda, and T. Oga Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease Respir Med. 94 2000 841 846
42. S.D. Aaron, K.L. Vandemheen, and J.J. Clinch Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation Chest. 121 2002 688 696
43. R. Benzo, P.A. Flume, D. Turner, and M. Tempest Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures J Cardiopulm Rehabil. 20 2000 231 234
44. P.L. Paggiaro, R. Dahle, I. Bakran, L. Frith, K. Hollingworth, and J. Efthimiou Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group Lancet. 351 1998 773 780
45. P.S. Burge, Calverley PMA, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive airways disease: the ISOLDE trial BMJ 320 2000 1297 1303
46. R. Pauwels, P. Calverley, and A.S. Buist COPD exacerbations: the importance of a standard definition Respir Med. 98 2004 99 107
47. R. Rodriguez-Roisin Toward a consensus definition for COPD exacerbations Chest. 117 5 Suppl 2 2000 398s 401s
48. Partridge M, Haughney J, Vogelmeier C, Ståhl E. Patient understanding of the term "exacerbations". The 100th International Conference of the American Thoracic Society, May 21-26, 2004. Orlando, Florida, USA.
49. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med. 157 1998 1418 1422
50. H. Doll, P. Grey-Amante, and I. Duprat-Lomon Quality of life in acute exacerbation of chronic bronchitis: results from a German population study Respir Med. 96 2002 39 51
51. P.W. Jones, and E. Sthl Reducing exacerbations leads to a better health-related quality of life in patients with COPD Eur Respir J 22 Suppl 45 2003 238S
52. T.A. Seemungal, R. Harper-Owen, and A. Bhowmik Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Am J Respir Crit Care Med. 164 2001 1618 1623
53. S. Spencer, P.W. Jones the GLOBE Study Group Time course of recovery of health status following an infective exacerbation of chronic bronchitis Thorax. 58 2003 589 593
54. F. Andersson, S. Borg, and S.A. Jansson The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med. 96 2002 700 708
55. P. Vermeire The burden of chronic obstructive pulmonary disease Respir Med. 96 Suppl C 2002 S3 S10
56. E.F. Wouters Economic analysis of the Confronting COPD survey: an overview of results Respir Med. 97 Suppl C 2003 S3 S14
57. J. Garcia-Aymerich, E. Farrero, and M.A. Felez Risk factors of readmission to hospital for a COPD exacerbation: a prospective study Thorax 58 2003 100 105
58. R.A. Pauwels, C.G. Lofdahl, and L.A. Laitinen Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med. 340 1999 1948 1953
59. J. Vestbo, T. Sorensen, P. Lange, A. Brix, P. Torre, and K. Viskum Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial Lancet. 353 1999 1819 1823
60. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med. 343 2000 1902 1909
61. V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, and S. Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax. 58 2003 399 404
62. S.J. Guthrie, K.M. Hill, and M.E. Muers Living with severe COPD. A qualitative exploration of the experience of patients in Leeds Respir Med. 95 2001 196 204
63. Haughney J, Löfdahl C-G, Larsson T, Berggren F. Conjoint analysis of patient perceptions of COPD exacerbations. The 100th International Conference of the American Thoracic Society, May 21-26, 2004. Orlando, Florida, USA.
64. A.M. Yohannes, J. Roomi, K. Waters, and M.J. Connolly Quality of life in elderly patients with COPD: measurement and predictive factors Respir Med. 92 1998 1231 1236
65. E. Sthl, S.A. Jansson, A.C. Jonsson, K. Svensson, B. Lundback, and F. Andersson Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD Health Qual Life Outcomes. 1 2003 18
66. J.E. Brazier, R. Harper, and N.M. Jones Validating the SF-36 health survey questionnaire: new outcome measure for primary care BMJ 305 1992 160 164
67. J.E. Ware, M. Kosinski, and Keller SD A 12-item Short-Form health survey: construction of scales and preliminary tests of reliability and validity Medical Care. 34 1996 220 233
68. G.H. Guyatt, L.B. Berman, M. Townsend, S.O. Pugsley, and L.W. Chambers A measure of quality of life for clinical trials in chronic lung disease Thorax. 42 1987 773 778
69. T. van der Molen, B.W. Willemse, S. Schokker, N.H. Ten Hacken, D.S. Postma, and E.F. Juniper Development, validity and responsiveness of the Clinical COPD Questionnaire Health Qual Life Outcome. 28 2003 13
70. B. Alemayehu, R.E. Aubert, R.A. Feifer, and L.D. Paul Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease Value Health. 5 2002 436 441
71. J.A. Johnson, S.J. Coons, A. Ergo, and G. Szava-Kovats Valuation of EuroQOL (EQ-5D) health states in an adult US sample Pharmacoeconomics. 13 1998 421 433
72. T. Hajiro, K. Nishimura, and P.W. Jones A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med. 159 1999 1874 1878
73. I. Murdoch, E. Stähl, L. Ahlström, and C-G. Löfdahl COPD: the impact of the disease from the patient perspective. Poster presented at the 99th International Conference of the American Thoracic Society Seattle, Washington, USA, 16-21 May 2003
74. I. Murdoch, E. Stähl, L. Ahlström, and C-G. Löfdahl Understanding patients' needs: the impact of COPD Eur Respir J 22 Suppl 45 2003 69S
75. J.G. van Manen, Bindels PJE, and F.W. Dekker Risk of depression in patients with chronic obstructive pulmonary disease and its determinants Thorax. 57 2002 412 416
76. P. Almagro, E. Calbo, and A. Ochoa de Echaguen Mortality after hospitalization for COPD Chest. 121 2002 1441 1448
77. A. Domingo-Salvany, R. Lamarca, and M. Ferrer Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med. 166 2002 680 685
78. T. Oga, K. Nishimura, M. Tsukino, S. Sato, and T. Haijro Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status Am J Respir Crit Care Med. 167 2003 544 549
79. A.F. Connors Jr., N.V. Dawson, and C. Thomas Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med. 154 1996 959 967
80. J.B. Soriano, J. Vestbo, N.B. Pride, V. Kiri, C. Maden, and W.C. Maier Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Eur Respir J 20 2002 819 825
81. J.B. Soriano, V.A. Kiri, N.B. Pride, and J. Vestbo Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients Am J Respir Med. 2 2003 67 74
82. D.E. Niewoehner, M.L. Erbland, and R.H. Deupree Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group N Engl J Med. 340 1999 1941 1947
83. D.S. Postma, I. Peters, E.J. Steenhuis, and H.J. Sluiter Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1 1988 22 26
84. M. Decramer, L.M. Lacquet, R. Fagard, and P. Rogiers Corticosteroids contribute to muscle weakness in chronic airflow obstruction Am J Respir Crit Care Med. 150 1994 11 16
85. O. Johnell, R. Pauwels, and C.G. Lofdahl Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler Eur Respir J 19 2002 1058 1063
86. M. Cazzola, F. Imperatore, and A. Salzillo Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia Chest. 114 1998 411 415
87. 2-agonists in the management of stable chronic obstructive pulmonary disease Drugs. 60 2000 307 320
88. T.L. Petty Definition, epidemiology, course, and prognosis of COPD Clin Cornerstone. 5 2003 1 10